Materialise NV (MTLS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Driven by Medical ...

GuruFocus.com10-25

Revenue: EUR68.7 million, up 14% year-over-year. Gross Margin: 57.2%, up from 56% in Q3 2023. Adjusted EBIT: EUR4.4 million, representing 6.4% of revenue. Net Profit: EUR3 million or EUR0.05 per share...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478987427?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3Avv1k1gFV.hHXJApnlD.g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/75a1aae9a6a06f0e32190e75a5ceb1af","is_english":true,"pubTime":"2024-10-25 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2478987427","market":"us","top_or_hot":-1,"title":"Materialise NV (MTLS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Driven by Medical ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: EUR68.7 million, up 14% year-over-year.\nGross Margin: 57.2%, up from 56% in Q3 2023.\nAdjusted EBIT: EUR4.4 million, representing 6.4% of revenue.\nNet Profit: EUR3 million or EUR0.05 per share...</p>\n\n<a href=\"https://finance.yahoo.com/news/materialise-nv-mtls-q3-2024-130029268.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Materialise NV (MTLS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Driven by Medical ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaterialise NV (MTLS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Driven by Medical ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/materialise-nv-mtls-q3-2024-130029268.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: EUR68.7 million, up 14% year-over-year.\nGross Margin: 57.2%, up from 56% in Q3 2023.\nAdjusted EBIT: EUR4.4 million, representing 6.4% of revenue.\nNet Profit: EUR3 million or EUR0.05 per share...</p>\n\n<a href=\"https://finance.yahoo.com/news/materialise-nv-mtls-q3-2024-130029268.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MTLS","symbol_name":"Materialise NV","start_time":0,"source_url":"https://finance.yahoo.com/news/materialise-nv-mtls-q3-2024-130029268.html","article_id":"2478987427","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3Avv1k1gFV.hHXJApnlD.g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/75a1aae9a6a06f0e32190e75a5ceb1af"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478987427","pubTimestamp":1729861229,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Gross Margin: 57.2%, up from 56% in Q3 2023.Adjusted EBIT: EUR4.4 million, representing 6.4% of revenue.Net Profit: EUR3 million or EUR0.05 per share.Net Cash Position: EUR63.1 million at the end of Q3.Medical Segment Revenue: Grew by more than 24%, accounting for 44% of total revenue.Adjusted EBITDA: EUR9.9 million, with a margin of 14.4%.Deferred Revenue: EUR47.4 million, with EUR41.1 million related to software licenses and maintenance fees.Free Cash Flow: Negative EUR3.1 million for Q3 2024.Full Year Revenue Guidance: EUR265 million to EUR275 million.Full Year Adjusted EBIT Guidance: EUR11 million to EUR14 million.GuruFocus has detected 2 Warning Signs with BOM:542904.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Materialise NV  reported strong quarterly revenues of EUR68.7 million, marking a growth of over 14% compared to the same quarter last year.Despite revenue growth, the Manufacturing segment's adjusted EBITDA margin was o","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MTLS":"Materialise NV"},"translate_title":"Materialise NV(MTLS)2024年第三季度收益看涨期权亮点：医疗推动收入强劲增长……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTLS":1},"content_text":"Revenue: EUR68.7 million, up 14% year-over-year.\nGross Margin: 57.2%, up from 56% in Q3 2023.\nAdjusted EBIT: EUR4.4 million, representing 6.4% of revenue.\nNet Profit: EUR3 million or EUR0.05 per share.\nNet Cash Position: EUR63.1 million at the end of Q3.\nMedical Segment Revenue: Grew by more than 24%, accounting for 44% of total revenue.\nSoftware Segment Revenue: Increased by 3%.\nManufacturing Segment Revenue: Grew by 9%.\nAdjusted EBITDA: EUR9.9 million, with a margin of 14.4%.\nDeferred Revenue: EUR47.4 million, with EUR41.1 million related to software licenses and maintenance fees.\nFree Cash Flow: Negative EUR3.1 million for Q3 2024.\nFull Year Revenue Guidance: EUR265 million to EUR275 million.\nFull Year Adjusted EBIT Guidance: EUR11 million to EUR14 million.\n\n\nWarning! GuruFocus has detected 2 Warning Signs with BOM:542904.\n\nRelease Date: October 24, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nMaterialise NV (NASDAQ:MTLS) reported strong quarterly revenues of EUR68.7 million, marking a growth of over 14% compared to the same quarter last year.\nThe Medical segment emerged as the strongest revenue generator, accounting for 44% of total revenue, with a growth of more than 24%.\nThe company achieved a gross margin of 57.2%, an improvement from 56% in the previous year.\nMaterialise NV (NASDAQ:MTLS) has made significant progress in its strategic priorities, particularly in the Medical and Software segments, with new partnerships and product developments.\nThe company maintains a strong net cash position of EUR63.1 million, indicating financial stability and capacity for future investments.\n\n Negative Points \n\nThe Manufacturing segment continues to face a challenging market environment, particularly with weak prototyping demand, resulting in lower profitability.\nDespite revenue growth, the Manufacturing segment's adjusted EBITDA margin was only 2.6%, highlighting profitability challenges.\nThe transition to a cloud and subscription-based business model in the Software segment has impacted nonrecurring revenue, which decreased by 12%.\nOperational startup of the new ACTech plant is expected to temporarily impact revenue in the fourth quarter.\nThe company remains conservative in its outlook for the fourth quarter due to weaker prototyping demand and integration costs from recent acquisitions.\n\n Q & A Highlights \nQ: Can you discuss the sustainability of growth and profitability in the Medical segment, and what EBITDA margins might look like if growth continues at the current pace? A: Brigitte de Vet-Veithen, CEO: The Medical segment still has significant potential for adopting personalized solutions, such as those for trauma patients. We are only scratching the surface of this market. As we scale, managing margins typically becomes easier, so we expect the profitability profile to remain strong.\nQ: What are the current flow-through margins for the Medical business? A: Koen Berges, CFO: The EBITDA margins for the Medical segment are currently around 30%, which is what we see flowing through to our bottom line.\nQ: How can profitability be improved in the Manufacturing segment, which currently has lower margins compared to Medical? A: Brigitte de Vet-Veithen, CEO: Scale will help improve margins. We are shifting focus from prototyping to end-use parts in segments like aerospace and medtech, where our expertise adds value. This transition should lead to healthier margins.\nQ: What is the expected impact of the ACTech plant ramp-up on OpEx and CapEx? A: Koen Berges, CFO: The ACTech plant's operational startup will impact revenue in Q4 due to capacity limitations during equipment transfers. We have invested about 65-70% of the total planned CapEx for the plant, with the remainder to be completed over the next 1-2 years.\nQ: How do the new software partnerships impact future growth, and what is the outlook for the Software segment? A: Brigitte de Vet-Veithen, CEO: Partnerships are crucial for providing end-to-end solutions without extensive R&D investments. They are expected to drive further adoption of our software solutions, supporting future growth.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478987427"}